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Background and Purpose: Endovascular thrombectomy (EVT) is effective for acute ischemic 
stroke with large vessel occlusion (LVO) and NIHSS ≥6. However, EVT benefit for mild deficits 
LVOs (NIHSS<6) is uncertain. We evaluated EVT efficacy and safety in mild strokes with LVO.
Methods: A retrospective cohort of patients with anterior circulation LVO and NIHSS<6 
presenting within 24hours from last-seen-normal were pooled. Patients were divided into 2 groups: 
EVT or medical management. 90day mRS=0–1 was the primary outcome; mRS=0–2 was the 
secondary. Symptomatic intracerebral hemorrhage (sICH) was the safety outcome. Clinical 
outcomes were compared through a multivariable logistic regression after adjusting for age, 
presentation NIHSS, time-last-seen-normal-to-presentation, center, IV-alteplase, ASPECTS, and 
thrombus location. We then performed propensity score matching as a sensitivity analysis. Results 
were also stratified by thrombus location.
Results: 214 patients (EVT-124, medical management-90) were included from 8 US and Spain 
centers between January/2012 and March/2017. The groups were similar in age, ASPECTS, IV-
alteplase rate and time-last-seen-normal-to-presentation. There was no difference in mRS=0–1 
between EVT and medical management (55.7% versus 54.4%, respectively, aOR=1.3, 
95%CI=0.64–2.64, p=0.47). Similar results were seen for mRS=0–2 (63.3% EVT versus 67.8% 
medical management, aOR=0.9, 95%CI=0.43–1.88, p=0.77). In a propensity matching analysis, 
there was no treatment effect in 62 matched pairs (53.5%EVT, 48.4% medical management; 
OR=1.17, 95%CI=0.54–2.52, p=0.69). There was no statistically significant difference when 
stratified by any thrombus location; M1 approached significance (p=0.07). sICH rates were higher 
with thrombectomy (5.8% EVT versus 0% medical management, p=0.02).
Conclusions: Our retrospective multicenter cohort study showed no improvement in excellent 
and independent functional outcomes in mild strokes (NIHSS<6) receiving thrombectomy 
irrespective of thrombus location, with increased sICH rates, consistent with the guidelines 
recommending the treatment for NIHSS≥6. There was a signal towards benefit with EVT only in 
M1 occlusions; however this needs to be further evaluated in future RCTs.
Keywords
Ischemic stroke; Large vessel occlusion; Mild stroke; Endovascular thrombectomy
Introduction
Endovascular thrombectomy (EVT) improved reperfusion rates and clinical outcomes over 
best medical management, including IV-alteplase, in multiple randomized control trials 
(RCTs) for selected stroke patients with large vessel occlusion (LVO).1–9 Based on these 
trials, current guidelines endorse EVT as the standard of care for patients with LVO in the 
anterior circulation (ICA and MCA/M1) with a National Institutes of Health Stroke Scale 
(NIHSS) score of 6 or more.10 This NIHSS cutoff was established because the previous 
RCTs’ eligibility criteria mostly excluded patients with NIHSS <6. One exception was MR 
CLEAN, which enrolled patients with NIHSS as low as 2.1 Consequently, only a restricted 
group of patients with mild strokes and LVO were included in those RCTs as illustrated in 
the HERMES pooled meta-analysis which had limited number of patients with NIHSS <10 
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and even fewer had NIHSS <6.11 Thus, there is a lack of evidence of EVT effectiveness and 
safety in this important subpopulation.
Many LVO patients presenting with NIHSS <6, however, can end up with significant 
disability. In the absence of data, physicians face uncertainty how to manage these patients, 
since relatively milder deficits may not seem to justify the risks of EVT. To help fill this gap 
in information, we explored the effectiveness and safety of EVT in LVO patients with mild 
strokes (NIHSS <6) in a large, multicenter dataset that reflects worldwide daily practice.
Materials and Methods
The data that support the findings of this study are available from the corresponding author 
upon reasonable request.
Study Design, Settings and Participants
We retrospectively pooled a cohort of acute ischemic stroke (AIS) patients from 8 USA and 
Spain centers with anterior circulation LVO and NIHSS <6 presenting within 24 hours from 
last-seen-normal between January, 2012 and March, 2017. LVO was defined as an occlusion 
of the anterior circulation (ICA, MCA: M1, M2, M3, M4, and, ACA) identified on the 
coronal CT angiogram, anterior-posterior projection of the magnetic resonance angiogram, 
or anterior-posterior conventional angiogram as read and adjudicated locally by the 
participating center. The study was approved by the institutional review boards of the 
participating centers (University of Texas, Houston, Texas; Valley Baptist Hospital, 
Harlingen, Texas; Kaiser Permanente, Los Angeles, California; University of Tennessee, 
Memphis; Kansas University, Kansas City; Baylor College of Medicine, Dallas, Texas; Rush 
University, Chicago, Illinois; and University Hospital Vall d’Hebron, Barcelona, Spain), 
which determined that informed consent was not required for this retrospective analysis.
Study Treatments, Exposures and Intervention
Patients were divided into EVT and medical management groups based on their locally 
determined treatment. Endovascular treatment included mechanical thrombectomy by means 
of retrievable stents, with or without adjunctive aspiration techniques. Primary aspiration or 
intra-arterial thrombolytics were given in some cases. Medical management was based on 
current AHA guidelines, including IV-alteplase in patients presenting within the first 4.5 
hours from last-seen-normal and meeting other guideline criteria. In patients not eligible for 
IV-alteplase, an antiplatelet agent was administered on day 1, unless there was an indication 
for early anticoagulation.
Demographics, Variables, and Measurements
Information on baseline demographics, vascular risk factors, last-seen-normal, admission 
blood glucose level, NIHSS score (range, 0–42, with higher scores indicating severe stroke), 
IV-alteplase administration and time, if applicable, and EVT center arrival time were 
obtained from the prospectively collected stroke registries of the different centers. Other 
clinical endpoints obtained included symptomatic intracerebral hemorrhage (sICH) (defined 
as a parenchymal hematoma grade 2 associated with worsening neurologic status thought to 
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be related to the hematoma), neurologic deterioration (defined as a ≥4-point increase in the 
NIHSS score), and functional outcome at 90 days as measured by modified Rankin Scale 
(range, 0–6, with lower scores indicating better outcomes). Type of mechanical 
thrombectomy device, intra-arterial thrombolytic, conscious sedation (CS) or general 
anesthesia (GA), groin puncture time, time to recanalization (mTICI ≥ 2b if achieved or end 
of procedure), and duration of the procedure were also reported from the respective centers’ 
databases.
Imaging Analysis
Early ischemic changes were measured by the Alberta Stroke Program Early Computed 
Tomographic Score (ASPECTS)12 on non–contrast-enhanced CT head scans. For 
recanalization, the modified Thrombolysis in Ischemic Stroke score (mTICI (range, 0 [no 
perfusion] to 3 [full perfusion with filling of all distal branches])13 was used; successful 
reperfusion (partial and complete) was defined as a modified score ≥ 2b at the end of the 
procedure. The CT and angiographic images were adjudicated locally at the treatment 
center.
Study Outcomes
90 day excellent outcome (mRS 0–1) was chosen as the primary outcome as it is a more 
appropriate goal for mild strokes than mRS 0–2. Independent outcome (mRS 0–2) was a 
secondary outcome. Rates of hemorrhage and symptomatic hemorrhage (SITS-MOST 
criteria14) were safety outcomes. Other outcomes included rates of asymptomatic 
hemorrhage (parenchymal hematoma (PH) type 1 and 2, and reperfusion in the EVT group 
measured by the modified Thrombolysis in Ischemic Strokes core (mTICI).13
Statistical Analysis
Demographics, baseline characteristics, and clinical outcomes in EVT patients were 
compared to those who had medical management by two sample t-test or Wilcoxon rank 
sum test as appropriate for continuous variables and Chi-square test or Fisher’s exact test as 
appropriate for categorical variables. Multivariable logistic regression was conducted to 
evaluate the differences in outcome between the two groups after adjustment for pre-
specified variables including age, presentation NIHSS, time last-seen-normal to EVT center 
arrival, center, IV-alteplase, ASPECTS, and thrombus location. We also explored whether 
there was any interaction between treatment differences and treatment time windows (0–6 
hours and >6–24 hours) from last-seen-normal to treatment time. Unadjusted odds ratio 
(OR) and adjusted OR (aOR) along with their 95% confidence intervals (CI) were reported.
We assessed the interaction between thrombectomy treatment effect and thrombus location. 
Further exploratory analysis was done to evaluate thrombus-location-specific differences in 
outcomes between the two treatment groups (EVT versus medical management) and 
thrombus location (M1, ICA, M2 and M3/M4/ACA) as well as dichotomized thrombus 
location (proximal: M1+ICA versus distal: M2+M3+M4+ACA).
Furthermore, we matched EVT and medical management patients using propensity scores. A 
multivariable logistic regression model was built to calculate propensity score for each 
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patient. The model included the following pre-specified variables: age, NIHSS, IV-alteplase, 
transfer status, wake-up stroke status, onset to arrival time, and thrombus location. We 
applied digit-based greedy approach15 to match patients. Initially, we matched EVT patients 
to medical management patients within all thrombus locations. In addition, we matched EVT 
and medical management patients within each dichotomized thrombus locations (proximal 
and distal). We assessed the distribution of patient characteristics between two groups in the 
matched samples through two sample t-test or Wilcoxon rank sum test as appropriate for 
continuous variables and Chi-square test or Fisher’s exact test for categorical variables. The 
odds ratio along with its 95% confidence interval based on conditional logistic regression 
were reported for the matched samples. All analyses were performed using SAS 9.4 (Cary, 
NC) and a two-sided p-value less than 0.05 was considered as statistically significant.
Results
Baseline Characteristics
214 patients were included; 124 received EVT and 90 medical management. The two groups 
had similar baseline age, ASPECTS, % IV-alteplase and median time (mins, IQR range) to 
EVT center as illustrated in Table 1. Medical management patients had milder strokes 
(median NIHSS: 3 versus 4, p=0.005) than EVT. Most patients had MCA occlusion (M1 or 
M2) (EVT 54.8%-M1 and 26.6%-M2) as compared to medical management (23.3%-M1 and 
48.9%-M2), while 16.9% of EVT and 13.3% of medical management patients had ICA 
occlusions (Table 1).
Clinical Outcomes Comparison
Tables 2 summarizes the ORs and aORs through multivariable regression analyses in the 
whole cohort and after stratification by thrombus location for excellent outcomes. There was 
no difference in excellent (mRS 0–1) outcome between the groups (55.7% EVT versus 
54.4% medical management, Figure 1A), aOR 1.30 (95% CI 0.64–2.64, p=0.47, Table 2). 
Similar results were seen for independent outcome (63.3% EVT versus 67.8% medical 
management), aOR 0.90 (95%CI=0.43–1.88, p=0.77)] (Table 1). There was no interaction 
between outcome differences with EVT versus medical management and time from last-
seen-normal to treatment time; early (0–6 hrs) versus late (>6–24 hrs) time windows 
(p=0.98).
Clinical Outcome Comparison by Thrombus Location
Patients with mild strokes due to proximal occlusions (M1 and ICA) were more likely to 
receive thrombectomy (54.8% and 16.9% EVT versus 23.3% and 13.3% medical 
management, respectively, p<0.001) while those with more distal occlusions (M2, M3/M4) 
were more likely to receive medical management only (26.6% and 1.6% EVT versus 48.9% 
and 14.4% medical management).
There was no statistically significant interaction between thrombectomy treatment effect and 
thrombus location (p=0.15). Since patients with more proximal occlusions are more likely to 
have larger areas at risk despite of mild deficits, we further explored if there was a potential 
treatment effect difference by the different thrombus location strata. The rates of excellent 
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outcomes were higher with EVT in patients with M1 occlusions (52.8% EVT versus 23.8% 
medical management, Figure 1B) and ICA (53.8% EVT versus 41.7% medical management, 
Figure 1C). For M1 occlusions, the aOR for excellent outcome was 3.31 (95%CI=0.92–
11.94, p=0.07) (Table 2). The difference approached but not did reach statistical significance 
for M1 occlusions, suggesting that patients with M1 occlusions might potentially benefit 
from thrombectomy. There was no statistical significance for ICA occlusions (aOR=1.95, 
95% CI=0.35, 10.77, p=0.44) (Table 2).
Conversely, it appeared that patients with more distal occlusions did not benefit with 
thrombectomy; M2 (64.3% EVT versus 72.7% medical management, Figure 1D) and 
M3/M4/ACA (0% EVT versus 53.8% medical management, Figure 1). Similar results were 
observed for the secondary outcome (mRS=0–2) (Table 1). When dichotomizing thrombus 
location into proximal (M1+ICA) and distal (M2+M3+M4+ACA), patients with proximal 
occlusions had more excellent outcomes with EVT that approached but did not reach 
statistical significance (53.1% EVT versus 30.3% medical management, aOR =2.68, 
95%CI=0.98–7.32, p=0.05) (Figure 2A, Table 2). There was no difference in excellent 
outcome rates in patients with distal occlusions (60% EVT versus 68.4% medical 
management, Figure 2B).
Clinical Outcome Comparison with Propensity Score Matching
We matched 62 pairs of EVT and medical management patients. The distributions of patient 
characteristics between two groups in the matched sample were similar (Table 2). There was 
no treatment effect for excellent outcome in the matched sample (53.5% EVT, 48.4% 
medical management; OR=1.17, 95%CI=0.54–2.52, p=0.69). Similar results were seen 
when matching within proximal and distal thrombus locations, respectively (Tables 3 and 4 
show baseline characteristics of the matched pairs in the two treatment groups). 32 pairs 
were matched within proximal thrombus location and 29 pairs were matched within distal 
with no difference in excellent outcomes with EVT for proximal thrombi (47.1% EVT, 
31.3% medical management; OR=1.67; 95%CI=0.40–6.97, p=0.48) or distal thrombi (56% 
EVT, 69% medical management; OR=0.78; 95%CI=0.29–2.09, p=0.62).
Safety Outcomes
There was no difference in the incidence of PH1 and PH2 (5.3% EVT versus 10% medical 
management, p=0.20) (Table 3). However, 5.8% of patients in the EVT group had sICH, as 
compared to none in the medical management group (p=0.02). Further analysis of patients 
who had sICH did not show any difference in IV-alteplase rate, ASPECTS, age, reperfusion 
times, NIHSS, history of HTN, or thrombus location as compared to those who did not have 
sICH (Table 4). We observed increased sICH with multiple passes during EVT (as compared 
to a single pass), but this difference did not reach significance (p=0.26).
There was a statistically significant association between sICH and mortality (p=0.01) and 
patients undergoing EVT had higher mortality (8.9% EVT versus 1.1 % medical 
management, p=0.03).
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Patients with milder strokes usually have independent outcome, but those with LVOs may 
face a different fate. In our cohort of patients with baseline NIHSS <6, one third (32.2%) of 
those receiving medical management had 90 day mRS >2. The benefit of EVT for LVO in 
milder stroke patients remains uncertain. A patient-level pooled meta-analysis of 5 RCTs 
showed no clear benefit of EVT in 177 patients across the entire NIHSS range 0 to 10 (aOR 
1.67 95%CI 0.80–3.50, p=0.45)11 but results in the cohort of patients with NIHSS <6 was 
not reported. These results are affected by the small number of patients pooled, since most 
of these RCTs’ inclusion criteria started at NIHSS threshold of 6 2−5 and MR CLEAN at 2.1 
This illustrates the need for data specifically in this subgroup of patients with mild strokes.
Prior studies have attempted to address outcomes with EVT in milder stroke patients but 
were limited by single center reporting,16 small sample size16–18 or lack of a concurrent 
medical management group.19 In a single center retrospective study, Haussen et al. reported 
a shift towards better discharge NIHSS in EVT patients (−2.5 versus 0, p<0.01) but there 
was no statistical difference in 90 day mRS 0–2 (100% EVT versus 77% medical 
management, p=0.15) or mRS 0–1 (70% versus 57% respectively p=0.19).16 An analysis of 
the GESTOR and STOPstroke databases with 26 matched pairs showed increased rates of 
independence with EVT at 90 days (93% versus 69%, p=0.04).18 In a 3 center single arm 
study of 138 patients with NIHSS ≤7, Dargazanli et al. reported excellent outcomes with 
EVT in 65% and independent outcomes in 78%,19 but there was no superiority of EVT 
when compared to medical management when the authors further evaluated data from the 
Endovascular Treatment in Ischemic Stroke (ETIS) cohort.20 Similarly, an analysis of 78 
patients with mild LVO stroke (NIHSS ≤5) from the multicenter SONIIA registry17 showed 
no benefit of EVT over medical treatment (58.8% EVT versus 68.2% medical management, 
p=0.39) with an excess of sICH in patients receiving EVT (11.8%). IV thrombolysis was the 
single independent predictor of independent outcome in that cohort. With 3 studies reporting 
no adjunctive benefit with EVT in this population and one reporting increased rates of 
independent outcomes, these inconclusive results emphasize the need for additional higher 
quality data in this population.
Our results showed there was no overall EVT treatment benefit in patients with NIHSS <6. 
In a secondary analysis comparing the two treatments stratified by thrombus location, 
patients with more proximal occlusions (ICA and M1) were more likely to receive EVT 
compared to those with more distal occlusions. Since patients with more proximal 
occlusions would, theoretically, have a larger area at risk, it is plausible that there would be 
an interaction between thrombectomy treatment effect and thrombus location. Our data did 
not support treatment effect modification by the overall thrombus location. We, however, 
conducted further exploratory analyses to look at treatment effect difference after stratifying 
by thrombus location. Although not statistically significant, and limited by small numbers, 
our analyses suggested that patients with more distal occlusions have better outcome with 
medical management. Furthermore, our data showed that there might be a potential 
treatment effect for patients with M1 occlusions as the difference approached statistical 
significance. These analyses need to be verified in other cohorts, hopefully with randomized 
data. If thrombectomy is to be studied further in LVO patients with NIHSS <6, our data 
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suggest that only patients with proximal occlusions should be the target population. 
Furthermore, we performed propensity matching as a sensitivity and confirmatory analysis 
and the results remained the same with no statistical significance in outcome differences 
between EVT and medical management groups.
In regards to safety outcomes, while the rate of disability was the same in both groups, EVT 
was associated with higher rates of sICH and mortality compared to medical management. 
These findings support the concerns around the safety of the intervention in this population 
and advocate for a careful approach when entertaining mild strokes with LVO for 
thrombectomy.
Our findings are limited by the retrospective design and lack of a randomized comparison 
group. While a randomized trial would provide the highest level of evidence, it may have 
significant feasibility challenges. RCT in this population would be difficult to power since 
there was no treatment effect when including all thrombus locations, difficult to enroll given 
the limited number of patients would meet the eligibility criteria if the trial was restricted to 
only proximal occlusions, and difficult to execute given the difficulty differentiating patients 
with one or two points differences in NIHSS (<6 versus ≥6). The lack of randomized data in 
this population is probably due to the fact that this is a challenging population to conduct an 
RCT on. Having said that, there are two RCTs that are currently being planned. These trials 
will bring conclusive answers and complement our data. In the meanwhile, however, our 
data serve as a good level of foundational evidence. The other limitation of our study is that 
although the EVT and medical management groups were mostly similar in baseline 
characteristics, the patients were from 8 centers with different EVT criteria where selection 
for thrombectomy was not randomized and was based on institutional protocols and treating 
physicians’ decisions. Selection bias might have occurred since those patients who were 
viewed as more likely to benefit from EVT were the ones treated with the intervention. 
Furthermore, there were differences in baseline characteristics and given the nature of the 
retrospective study, treatment decision was not randomized or prospectively protocolized. 
We attempted to account for these treatment patterns by utilizing multivariable regression 
models for adjustment and performing propensity matching analyses but this might not have 
completely accounted for selection biases, as patients who were felt to benefit from 
thrombectomy by the treating physicians were undoubtedly selected for the treatment. While 
we adjusted for variables known to affect clinical outcomes, the lack of randomization 
prevented us from accounting for unmeasured covariates. We only have data on CT changes 
(ASPECTS) as a baseline imaging modality and we considered that in our analyses. Other 
advanced imaging modalities, which further evaluate ‘at risk’ tissue, such as CT Perfusion, 
magnetic resonance perfusion, and collateral status might have been taken into consideration 
to guide treatment decisions.
The strength of our data is that it represents a large cohort derived from real world daily 
practice with a concurrent medical management group.
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Our retrospective multicenter cohort study showed no increase in excellent and independent 
functional outcomes in patients receiving EVT, with increased rates of sICH and mortality 
rates. These findings are consistent with the current guidelines that recommend the treatment 
only in patients with NIHSS ≥6.
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Modified Rankin Scale scores (mRS) at 90 days compared between endovascular 
thrombectomy and medical management for all thrombus locations
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Modified Rankin Scale scores (mRS) at 90 days compared between endovascular 
thrombectomy and medical management for M1 thrombus location
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Modified Rankin Scale scores (mRS) at 90 days compared between endovascular 
thrombectomy and medical management for ICA thrombus location
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Modified Rankin Scale scores (mRS) at 90 days compared between endovascular 
thrombectomy and medical management for M2 thrombus location
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Modified Rankin Scale scores (mRS) at 90 days compared between endovascular 
thrombectomy and medical management for proximal (M1+ICA) thrombus location
Sarraj et al. Page 16














Modified Rankin Scale scores (mRS) at 90 days compared between endovascular 
thrombectomy and medical management for distal (M2+M3+M4+ACA) thrombus location
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Table 1.
Baseline characteristics of EVT and medical management patients
Variable EVT (N=124) Medical Management (N=90) P value
Age, years (mean ±SD) 65.8±15.5 65.4±16.2
0.85
*















Blood glucose level, mg/dL
Median (Q1, Q3)
118.0 (101.0, 158.0) 115.0 (101.0, 150.0)
0.92
‡
Hypertension, % 70.2 80.0
0.10
†
Type II Diabetes, % 29.0 30.0
0.88
†
Wake up strokes, % 17.7 13.3
0.40
†
Transfers, % 20.5 45.6
<.001
†
IV-alteplase given, % 31.4 32.2
0.90
†
























ASPECTS (mean ±SD) 9.7±0.9 9.4±1.1
0.11
*
Onset to EVT arrival time, minutes
Median (Q1, Q3)




0 83.1 − −
1 9.2 −
2a 7.7 −
Last-seen-normal to reperfusion time, minutes
Median (Q1, Q3)
350.0 (268.0, 574.0) − −
*
denotes p-values obtained by two sample t-test
†
denotes p-values obtained by Chi-square test
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‡
denotes p-values obtained by Wilcoxon rank sum test
§
denotes p-values obtained by Fisher’s exact test
NIHSS: National Institute of Health Stroke Scale, EVT: Endovascular Thrombectomy, ICA: Internal Carotid Artery, M1: Middle Cerebral 
Artery/M1 segment occlusion, M2: Middle Cerebral Artery/M2 segment occlusion, M3: Middle Cerebral Artery/M3 segment occlusion, M4: 
Middle Cerebral Artery/M4 segment occlusion, mTICI: the modified Thrombolysis in Ischemic Stroke score, ASPECTS: The Alberta stroke 
program early CT score, IV-alteplase: Intra Venous Tissue Plasminogen Activator
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Table 2.
Excellent outcome rates (mRS 0–1), unadjusted and adjusted ORs, between EVT and medical management 
only stratified by thrombus location
Excellent outcome (mRS 0–1) % Excellent outcome (mRS 0–1)
Thrombus Location EVT Medical Management OR (95% CI) P value aOR (95%CI) P value
All (n=214) 55.7 54.4 1.05 (0.57, 1.93) 0.87 1.30 (0.64, 2.64) 0.47
M1 (n=89) 52.8 23.8 3.58 (1.07, 11.97) 0.04 3.31 (0.92, 11.94) 0.07
ICA (n=33) 53.8 41.7 1.63 (0.33, 8.05) 0.54 1.95 (0.35, 10.77) 0.44
Proximal*(n=122) 53.1 30.3 2.60 (1.02, 6.64) 0.05 2.68 (0.98, 7.32) 0.05
M2 (n=77) 64.3 72.7 0.68 (0.24, 1.88) 0.45 0.68 (0.23, 2.01) 0.48




60 68.4 0.69 (0.27, 1.75) 0.43 0.70 (0.26, 1.87) 0.47
*
Proximal occlusions included M1+ICA
†
Distal occlusions included M2+M3/M4/ACA













Sarraj et al. Page 21
Table 3.
Clinical and radiographical outcomes
Variable EVT Medical Management Total P value
Asymptomatic hemorrhage, % 7.9 10.0 8.8
0.60
†
Symptomatic hemorrhage, % 5.8 0.0 3.3
0.02
§
PH1, % 5.3 10.0 7.4
0.20
†
PH2, % 94.7 90.0 92.6
0.20
†
90 day mRS, %
  0 36.7 33.3 34.9
  1 19.0 21.1 20.1
  2 7.6 13.3 10.7
  3 10.1 17.8 14.2
  4 16.5 11.1 13.6
  5 1.3 2.2 1.8
  6 8.9 1.1 4.7
Excellent outcome at 90 days, % 55.7 54.4 55.0
0.87
†
Independent outcome at 90 days, % 63.3 67.8 65.7
0.54
†
Post procedure mTICI score, %
  0 12.3 12.3
  1 0.9 0.9
  2a 8.8 8.8
  2b 21.9 21.9
  3 56.1 56.1
†
Denotes p-values obtained by Chi-square test
§
denotes p-values obtained by Fisher’s exact test
mRS: Modified Rankin Scale, EVT: Endovascular Thrombectomy, mTICI: the modified Thrombolysis in Ischemic Stroke sxscore
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Table 4.
Characteristics of EVT patients with sICH and without sICH
Variable sICH Non-sICH P value
Age, Mean ± SD 68.0±14.7 65.6±15.6
0.69
*
ASPECTS, Mean ± SD 9.5±0.8 9.7±0.9
0.67
*
IV-alteplase given, % 14.3 32.4
0.43
§
Last-seen-normal to reperfusion time, Median (Q1, Q3) 497.5 (453.5, 802.5) 340.0 (261.0, 574.0)
0.11
‡
NIHSS at presentation, Median (Q1, Q3) 3.0 (0.0, 4.0) 4.0 (2.0, 5.0)
0.17
‡






 M1 MCA 57.1 54.4
 M2 MCA 42.9 25.4
 M3/M4 ACA 0.0 1.8
 Proximal or Distal ICA 0.0 18.4
Number of Passes, %
0.26
§
 Single 28.6 52.6
 Multiple 71.4 47.4
*
denotes p-values obtained by two sample t-test
‡
denotes p-values obtained by Wilcoxon rank sum test
§
denotes p-values obtained by Fisher’s exact test
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